Skip to main content

Global Newsroom

CSL Behring Patient Zahra Khan, living with hereditary angioedema

Global Newsroom

Recent News Releases

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Sep 5, 2023

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response...

Read more news from CSL

Recent News Releases
Jun 20, 2023

HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus...

Read more news from CSL Behring

Recent News Releases
Sep 18, 2023

CSL Seqirus presents new data at the 9th ESWI meeting on the impact of effective vaccination campaigns to protect healthcare systems across the world.1,2 The French data highlights how vaccines...

Read more news from CSL Seqirus

Recent News Releases
Aug 28, 2023

The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject®...

Read more news from CSL Vifor

Read all company news releases

Media Contacts

Victoria, Australia
Phone: +61 0450 909 211

CSL Behring
North America


Asia Pacific

CSL Seqirus
EMEA and Latam
Emmanuella Dekonor
Phone: +44 7920500496

North America
Tiffany Cody
Phone: +1 908 370 1863

Asia Pacific
Hamish Walsh
Phone: 0422 424 338

CSL Plasma
United States

Follow Us Online
  • linkedin icon
  • twitter icon
  • youtube icon
  • facebook icon
  • instagram icon
Get our latest news releases in your inbox
* Required Fields